Phase 2 Major Depressive Disorder (MDD) Clinical Trials
9 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–9 of 9 trials
Recruiting
Phase 2
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
Major Depressive Disorder (MDD)
Draig Therapeutics Ltd300 enrolled40 locationsNCT07300969
Recruiting
Phase 2
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
Major Depressive Disorder (MDD)Depressive Disorder, Treatment-Resistant
ACADIA Pharmaceuticals Inc.153 enrolled13 locationsNCT07284667
Recruiting
Phase 2
Dextromethorphan-Bupropion on Striatal Activity in Adults With Major Depressive Disorder
Major Depressive Disorder (MDD)
Roger McIntyre30 enrolled1 locationNCT07523048
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
Major Depressive Disorder (MDD)Major Depressive Disorder With Anxious Distress
Seaport Therapeutics360 enrolled45 locationsNCT07065240
Recruiting
Phase 2
Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
Major Depressive Disorder (MDD)
Supernus Pharmaceuticals, Inc.230 enrolled1 locationNCT07226661
Recruiting
Phase 2
A Clinical Trial of Add-on Oral Slow-release Ketamine Treatment in Major Depression
Major Depressive Disorder (MDD)
Daniel Lindqvist12 enrolled1 locationNCT07396272
Recruiting
Phase 2
Orexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical Trial
Major Depressive Disorder (MDD)Suicide Risk
Marianne Goodman30 enrolled1 locationNCT06854224
Recruiting
Phase 2Phase 3
Understanding and Treating Suicidal Ideation With Ketamine
Suicidal IdeationMajor Depressive Disorder (MDD)
The Royal's Institute of Mental Health Research36 enrolled1 locationNCT06891300
Completed
Phase 2
Assessing the effects of Lysergic acid diethylamide (LSD) microdosing in people experiencing depression (LSDDEP2)
Major Depressive Disorder (MDD)
The University of Auckland90 enrolled1 locationACTRN12624000128594